Nue Life vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Telehealth platform for ketamine-assisted therapy for treatment-resistant depression and PTSD; oral ketamine with coaching at home; licensed physician oversight with published outcomes data.
About
Nue Life is a Miami-based mental health company that provides at-home ketamine-assisted therapy for treatment-resistant depression, anxiety, PTSD, and OCD through a telehealth model. The company pairs oral ketamine with therapeutic coaching and integration support to treat patients who have not responded to traditional antidepressants. Nue Life's model addresses barriers to ketamine therapy — geographic access to ketamine clinics and prohibitive out-of-pocket costs — by delivering treatment at home with telehealth physician oversight and licensed therapist integration support. The platform has treated thousands of patients with documented outcomes data and published case studies. Nue Life operates in the rapidly growing psychedelic-assisted therapy market, which has seen significant clinical validation for ketamine and clinical trial progress for MDMA and psilocybin. Founded in 2020, the company has raised funding to expand access to ketamine therapy while the regulatory environment for psychedelic medicine continues to evolve.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.